Leads Biolabs Doses First Patient in LBL-047 Phase I Part B Trial
Leads Biolabs says it has dosed the first patient with systemic lupus erythematosus in Part B of its Phase I trial of LBL-047, a BDCA2/TACI bifunctional fusion protein.
Leads Biolabs says it has dosed the first patient with systemic lupus erythematosus in Part B of its Phase I trial of LBL-047, a BDCA2/TACI bifunctional fusion protein.